New perspectives on osteogenesis imperfecta

被引:507
作者
Forlino, Antonella [1 ,2 ]
Cabral, Wayne A. [1 ]
Barnes, Aileen M. [1 ]
Marini, Joan C. [1 ]
机构
[1] NICHD, Bone & Extracellular Matrix Branch, NIH, Bethesda, MD 20892 USA
[2] Univ Pavia, Dept Biochem, Sect Med & Pharm, I-27100 Pavia, Italy
关键词
EHLERS-DANLOS-SYNDROME; CARBOXYL-TERMINAL PROPEPTIDE; CARTILAGE-ASSOCIATED PROTEIN; TELOPEPTIDE LYSYL HYDROXYLASE; TRANSCRIPTION FACTOR OSTERIX; HYPEROSTOSIS CAFFEY-DISEASE; EMBRYONIC LETHAL MUTATION; PROCOLLAGEN N-PROTEINASE; ALPHA-1(I) COLLAGEN GENE; GROWTH-HORMONE TREATMENT;
D O I
10.1038/nrendo.2011.81
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
A new paradigm has emerged for osteogenesis imperfecta as a collagen-related disorder. The more prevalent autosomal dominant forms of osteogenesis imperfecta are caused by primary defects in type I collagen, whereas autosomal recessive forms are caused by deficiency of proteins which interact with type I procollagen for post-translational modification and/or folding. Factors that contribute to the mechanism of dominant osteogenesis imperfecta include intracellular stress, disruption of interactions between collagen and noncollagenous proteins, compromised matrix structure, abnormal cell-cell and cell-matrix interactions and tissue mineralization. Recessive osteogenesis imperfecta is caused by deficiency of any of the three components of the collagen prolyl 3-hydroxylation complex. Absence of 3-hydroxylation is associated with increased modification of the collagen helix, consistent with delayed collagen folding. Other causes of recessive osteogenesis imperfecta include deficiency of the collagen chaperones FKBP10 or Serpin H1. Murine models are crucial to uncovering the common pathways in dominant and recessive osteogenesis imperfecta bone dysplasia. Clinical management of osteogenesis imperfecta is multidisciplinary, encompassing substantial progress in physical rehabilitation and surgical procedures, management of hearing, dental and pulmonary abnormalities, as well as drugs, such as bisphosphonates and recombinant human growth hormone. Novel treatments using cell therapy or new drug regimens hold promise for the future.
引用
收藏
页码:540 / 557
页数:18
相关论文
共 216 条
[1]
Mutations in the Gene Encoding the RER Protein FKBP65 Cause Autosomal-Recessive Osteogenesis Imperfecta [J].
Alanay, Yasemin ;
Avaygan, Hrispima ;
Camacho, Natalia ;
Utine, G. Eda ;
Boduroglu, Koray ;
Aktas, Dilek ;
Alikasifoglu, Mehmet ;
Tuncbilek, Ergul ;
Orhan, Diclehan ;
Bakar, Filiz Tiker ;
Zabel, Bernard ;
Superti-Furga, Andrea ;
Bruckner-Tuderman, Leena ;
Curry, Cindy J. R. ;
Pyott, Shawna ;
Byers, Peter H. ;
Eyre, David R. ;
Baldridge, Dustin ;
Lee, Brendan ;
Merrill, Amy E. ;
Davis, Elaine C. ;
Cohn, Daniel H. ;
Akarsu, Nurten ;
Krakow, Deborah .
AMERICAN JOURNAL OF HUMAN GENETICS, 2010, 86 (04) :551-559
[2]
Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis [J].
Antoniazzi, F ;
Bertoldo, F ;
Mottes, M ;
Valli, M ;
Sirpresi, S ;
Zamboni, G ;
Valentini, R ;
Tato, L .
JOURNAL OF PEDIATRICS, 1996, 129 (03) :432-439
[3]
GH in combination with bisphosphonate treatment in osteogenesis imperfecta [J].
Antoniazzi, Franco ;
Monti, Elena ;
Venturi, Giacomo ;
Franceschi, Roberto ;
Doro, Francesco ;
Gatti, Davide ;
Zamboni, Giorgio ;
Tato, Luciano .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2010, 163 (03) :479-487
[4]
BACHINGER HP, 1987, J BIOL CHEM, V262, P17144
[5]
Clinical Review: Bisphosphonate Use in Childhood Osteoporosis [J].
Bachrach, Laura K. ;
Ward, Leanne M. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (02) :400-409
[6]
Baek WY, 2009, J BONE MINER RES, V24, P1055, DOI [10.1359/JBMR.081248, 10.1359/jbmr.081248]
[7]
Generalized Connective Tissue Disease in Crtap-/- Mouse [J].
Baldridge, Dustin ;
Lennington, Jennifer ;
Weis, MaryAnn ;
Homan, Erica P. ;
Jiang, Ming-Ming ;
Munivez, Elda ;
Keene, Douglas R. ;
Hogue, William R. ;
Pyott, Shawna ;
Byers, Peter H. ;
Krakow, Deborah ;
Cohn, Daniel H. ;
Eyre, David R. ;
Lee, Brendan ;
Morello, Roy .
PLOS ONE, 2010, 5 (05)
[8]
CRTAP and LEPRE1 Mutations in Recessive Osteogenesis Imperfecta [J].
Baldridge, Dustin ;
Schwarze, Ulrike ;
Morello, Roy ;
Lennington, Jennifer ;
Bertin, Terry K. ;
Pace, James M. ;
Pepin, Melanie G. ;
Weis, MaryAnn ;
Eyre, David R. ;
Walsh, Jennifer ;
Lambert, Deborah ;
Green, Andrew ;
Robinson, Haynes ;
Michelson, Melonie ;
Houge, Gunnar ;
Lindman, Carl ;
Martin, Judith ;
Ward, Jewell ;
Lemyre, Emmanuelle ;
Mitchell, John J. ;
Krakow, Deborah ;
Rimoin, David L. ;
Cohn, Daniel H. ;
Byers, Peter H. ;
Lee, Brendan .
HUMAN MUTATION, 2008, 29 (12) :1435-1442
[9]
Defective collagen crosslinking in bone, but not in ligament or cartilage, in Bruck syndrome: Indications for a bone-specific telopeptide lysyl hydroxylase on chromosome 17 [J].
Bank, RA ;
Robins, SP ;
Wijmenga, C ;
Breslau-Siderius, LJ ;
Bardoel, AFJ ;
Van der Sluijs, HA ;
Pruijs, HEH ;
TeKoppele, JM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (03) :1054-1058
[10]
Pyridinium cross-links in bone of patients with osteogenesis imperfecta: Evidence of a normal intrafibrillar collagen packing [J].
Bank, RA ;
Tekoppele, JM ;
Janus, GJM ;
Wassen, MHM ;
Pruijs, HEH ;
van der Sluijs, HAH ;
Sakkers, RJB .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (07) :1330-1336